Nothing Special   »   [go: up one dir, main page]

MXPA04006571A - Derivado de pirimidina biciclica fusionada. - Google Patents

Derivado de pirimidina biciclica fusionada.

Info

Publication number
MXPA04006571A
MXPA04006571A MXPA04006571A MXPA04006571A MXPA04006571A MX PA04006571 A MXPA04006571 A MX PA04006571A MX PA04006571 A MXPA04006571 A MX PA04006571A MX PA04006571 A MXPA04006571 A MX PA04006571A MX PA04006571 A MXPA04006571 A MX PA04006571A
Authority
MX
Mexico
Prior art keywords
fused bicyclic
pyrimidine derivatives
bicyclic pyrimidine
ring
receptor antagonism
Prior art date
Application number
MXPA04006571A
Other languages
English (en)
Inventor
Shigeru Izawa
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of MXPA04006571A publication Critical patent/MXPA04006571A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un derivado novedoso de pirimidina biciclica fusionada o un sal del mismos que actua como un antagonista del receptor de taquicinina y, en particular, como un antagonista del receptor NK1, esta representado por la siguiente formula general (1):(ver formula 1),en la cual los anillos A y B son cada uno un anillo de benceno que puede incluir de 1 a 3 sustituyentes (de los cuales cualesquiera dos adyacentes pueden unirse uno con el otro para formar un anillo); el anillo C es un anillo nitrogenado, m es 1 o 2; y n es 2 o 3.
MXPA04006571A 2002-01-18 2003-01-15 Derivado de pirimidina biciclica fusionada. MXPA04006571A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002009373 2002-01-18
PCT/JP2003/000263 WO2003062245A1 (fr) 2002-01-18 2003-01-15 Derives de pyrimidine fusionnes bicycliques

Publications (1)

Publication Number Publication Date
MXPA04006571A true MXPA04006571A (es) 2004-10-04

Family

ID=27605963

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006571A MXPA04006571A (es) 2002-01-18 2003-01-15 Derivado de pirimidina biciclica fusionada.

Country Status (14)

Country Link
US (1) US6995153B2 (es)
EP (1) EP1473295B1 (es)
JP (1) JP4417720B2 (es)
KR (1) KR100887471B1 (es)
CN (1) CN1297559C (es)
AT (1) ATE427310T1 (es)
AU (1) AU2003201885B2 (es)
BR (1) BR0307156A (es)
CA (1) CA2472835A1 (es)
DE (1) DE60326933D1 (es)
MX (1) MXPA04006571A (es)
NO (1) NO20043425L (es)
NZ (1) NZ533540A (es)
WO (1) WO2003062245A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005019225A1 (ja) * 2003-08-21 2007-11-01 杏林製薬株式会社 Ｎｋ１受容体拮抗作用を有する化合物の製造方法及びその製造中間体
CA2543552A1 (en) * 2003-10-27 2005-05-06 Novartis Ag Use of neurokinin antagonists in the treatment of urinary incontinence
EP2018863B9 (en) * 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US20090036425A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
FR2986232B1 (fr) * 2012-01-26 2014-02-14 Sanofi Sa Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2019162519A1 (en) 2018-02-26 2019-08-29 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
US20220162229A1 (en) * 2019-04-09 2022-05-26 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3952878A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
SG11202110615TA (en) 2019-04-09 2021-10-28 Nuvation Bio Inc Heterocyclic compounds and uses thereof
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263498B (es) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
DE69628484T2 (de) * 1995-03-24 2004-05-19 Takeda Chemical Industries, Ltd. Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives

Also Published As

Publication number Publication date
US20050085469A1 (en) 2005-04-21
EP1473295A1 (en) 2004-11-03
ATE427310T1 (de) 2009-04-15
KR100887471B1 (ko) 2009-03-10
BR0307156A (pt) 2004-12-07
DE60326933D1 (de) 2009-05-14
AU2003201885B2 (en) 2007-08-30
EP1473295A4 (en) 2005-12-28
CN1620459A (zh) 2005-05-25
WO2003062245A1 (fr) 2003-07-31
KR20040072732A (ko) 2004-08-18
NO20043425L (no) 2004-08-17
JPWO2003062245A1 (ja) 2005-05-19
CA2472835A1 (en) 2003-07-31
JP4417720B2 (ja) 2010-02-17
US6995153B2 (en) 2006-02-07
NZ533540A (en) 2006-04-28
EP1473295B1 (en) 2009-04-01
CN1297559C (zh) 2007-01-31

Similar Documents

Publication Publication Date Title
BRPI0414592A (pt) antagonistas de receptores de trombina
EA200500017A1 (ru) Новые соединения
WO2003068750A1 (fr) Inhibiteur de jnk
GB0130347D0 (en) Compounds
IL155875A0 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
MXPA04006571A (es) Derivado de pirimidina biciclica fusionada.
ATE225349T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
RS51146B (sr) Novi difenil-azetidinon sa poboljšanim fiziološkim osobinama postupak za njegovu proizvodnju,lekovi koji sadrže ovo jedinjenje i njihova upotreba
TR200102178T2 (tr) CRF reseptör antagonistleri ve bunlarla ilgili yöntemler.
GEP20074125B (en) Pyrazolopyridines and methods of making and using the same
DE60302157D1 (de) Opioidrezeptorantagonisten
WO2004112704A3 (en) Substituted piperidine compounds and methods of their use
WO2004111000A3 (en) Piperidyl derivatives and their use as tachykinin antagonists
EP1496059A4 (en) CONDENSED BICYCLIC PYRIMIDINE DERIVATIVES
ATE250058T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DE60102231D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
PL375350A1 (en) Indol derivatives and their use as 5-ht ligands
EP1457493A4 (en) CONDENSED, BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS
MXPA04004020A (es) Tien-3-ilsulfonilamino(tio)carbonil-triazolin(tio)onas substituidas.
EP1489083A4 (en) BICYCLIC PYRIMIDINE DERIVATIVE AND FUSIONED AS ANTAGONIST OF TACHYKININ RECEPTORS
YU39603A (sh) Jedinjenja piperazinilpirazina kao antagonisti serotonin 5-ht2 receptora
ITVR20020030A0 (it) Miscela per polvere di saldatura, nonche procedimento per l'impiego di detta miscela.

Legal Events

Date Code Title Description
FG Grant or registration